BioXcel Therapeutics Inc (OQ:BTAI)

Mar 25, 2024 07:00 am ET
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has entered into a...
Mar 15, 2024 07:00 am ET
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today reported that the European Patent Office (EPO) granted the...
Mar 12, 2024 07:00 am ET
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today provided an update on its late-stage TRANQUILITY and SERENITY...
Mar 01, 2024 07:00 am ET
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year...
Feb 14, 2024 08:30 am ET
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
FN Media Group News Commentary - Recent reports project that the anal cancer market will continue its recent growth through 2030. An article on the MD Anderson website. It said: “More than 8,000 people in the U.S. are diagnosed with anal cancer...
Feb 13, 2024 09:00 am ET
BioXcel Therapeutics Announces Termination of Proposed Public Offering
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has terminated its proposed public offering of...
Feb 12, 2024 08:31 am ET
Thinking about buying stock in BioXcel Therapeutics, Hitek Global, Abeona Therapeutics, Mullen Automotive, or Intuitive Machines?
NEW YORK, Feb. 12, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BTAI, HKIT, ABEO, MULN, and LUNR.
Feb 12, 2024 07:14 am ET
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that the U.S. Food and Drug Administration (FDA) has...
Feb 09, 2024 09:00 pm ET
BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) on behalf of long-term stockholders following a class action complaint that was...
Feb 08, 2024 04:01 pm ET
BioXcel Therapeutics Announces Proposed Public Offering
BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has commenced an...
Feb 06, 2024 07:00 am ET
BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced the completion of patient enrollment in the safety...
Feb 05, 2024 08:31 am ET
Thinking about buying stock in Cano Health, Vaxart, Macy's, Albemarle Corp, or BioXcel Therapeutics?
NEW YORK, Feb. 5, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANO, VXRT, M, ALB, and BTAI.
Feb 05, 2024 07:00 am ET
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that the United States Patent and Trademark Office...
Dec 12, 2023 07:00 am ET
BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today
As previously announced, BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, will host a virtual Neuroscience...
Dec 11, 2023 07:00 am ET
BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor...
Dec 01, 2023 06:29 pm ET
Moore Kuehn, PLLC Encourages BioXcel Therapeutics, Inc. Investors to Contact Law Firm
NEW YORK, Dec. 1, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against:
Nov 30, 2023 07:00 am ET
BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a virtual Neuroscience...
Nov 14, 2023 08:31 am ET
Thinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin?
NEW YORK, Nov. 14, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HRYU, ABSI, SPRO, BTAI, and CYBN.
Nov 14, 2023 07:00 am ET
BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced alignment with the FDA’s recommendation for...
Nov 08, 2023 07:00 am ET
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocar
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced positive overall survival (OS) data from its Phase 2...
Nov 06, 2023 07:00 am ET
BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced an update on the National Institute on Drug Abuse (NIDA)-funded trial...
Oct 31, 2023 07:00 am ET
BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will release its third quarter 2023 financial results on Tuesday,...
Oct 30, 2023 07:00 am ET
BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a...
Oct 26, 2023 09:31 am ET
Thinking about buying stock in Vista Energy, Ault Alliance, ATAI Life Sciences, LianBio, or BioXcel Therapeutics?
NEW YORK, Oct. 26, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIST, AULT, ATAI, LIAN, and BTAI.
Oct 25, 2023 07:00 am ET
BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced positive findings from an independent third party audit of the data from a...
Oct 11, 2023 09:00 pm ET
BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) on behalf of long-term stockholders following a class action complaint that was filed against BioXcel on July 7, 2023 with a Class Period from December 15, 2021 to June 28, 2023. Our investigation concerns whether the board of directors of BioXcel have breached their fiduciary duties to the company.
Oct 10, 2023 09:31 am ET
Thinking about buying stock in Immunic, BioXcel Therapeutics, Coherent Corp, Emx Royalty, or Lexicon Pharmaceuticals?
NEW YORK, Oct. 10, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMUX, BTAI, COHR, EMX, and LXRX.
Oct 10, 2023 07:00 am ET
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced positive overall survival (OS) data from its Phase 2...
Oct 05, 2023 09:31 am ET
Thinking about buying stock in Vivos Therapeutics, Twin Ridge Capital Acquisition, BioXcel Therapeutics, Cocrystal Pharma, or Cambium Networks?
NEW YORK, Oct. 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VVOS, TRCA, BTAI, COCP, and CMBM.
Oct 04, 2023 07:00 am ET
BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience, today provided an update on recent developments with its late-stage clinical...
Sep 30, 2023 07:00 pm ET
Lifshitz Law PLLC Announces Investigations of ImmunityBio, Inc. (NASDAQ: IBRX), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), Baxter International Inc. (NYSE: BAX)
ImmunityBio, Inc. (NASDAQ: IBRX) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements...
Sep 26, 2023 12:27 pm ET
Investigation Alert BAX, DHR, BTAI, and IBRX: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
Baxter International, Inc. (NYSE: BAX) Johnson Fistel, LLP is investigating potential claims on behalf of Baxter International, Inc. (NYSE: BAX). If you are a current, long-term shareholder of Baxter International, continuously holding your...
Sep 05, 2023 12:27 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc.(BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were...
Sep 05, 2023 11:06 am ET
DEADLINE ALERT for BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 05, 2023 06:00 am ET
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 04, 2023 01:30 pm ET
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LAS ANGELES, CA / ACCESSWIRE / September 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 04, 2023 11:46 am ET
FINAL DEADLINE REMINDER FOR BTAI INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against BioXcel Therapeutics, Inc. (BTAI
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut against BioXcel Therapeutics, Inc....
Sep 04, 2023 10:23 am ET
BTAI DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important September 5 Deadline in Secur
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”), of the important September 5, 2023 lead plaintiff deadline.
Sep 02, 2023 07:00 pm ET
Lifshitz Law PLLC Announces Investigations of Arrow Financial Corp. (NASDAQ: AROW), ImmunityBio, Inc. (NASDAQ: IBRX), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), and Baxter International Inc. (NYSE: BA
Arrow Financial Corp. (NASDAQ: AROW) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements...
Sep 01, 2023 09:00 pm ET
BIOXCEL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioXcel Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) in the United States District Court for the District of Connecticut on behalf of all persons and entities who purchased or otherwise acquired BioXcel securities between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”). Investors have until September 5, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Sep 01, 2023 07:14 pm ET
BIOXCEL 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioXcel Ther
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 5, 2023 to file lead plaintiff applications in a securities class action lawsuit against BioXcel Therapeutics, Inc. (NasdaqCM: BTAI), if they purchased the Company’s securities between December 15, 2021 and June 28, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Connecticut.
Sep 01, 2023 12:30 pm ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)
The Law Offices of Frank R. Cruz reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ:
Sep 01, 2023 11:58 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI
Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Sep 01, 2023 03:00 am ET
4-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 31, 2023 12:49 pm ET
SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc.(BTAI) Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws. Class Period: December 15, 2021 to June...
Aug 31, 2023 09:15 am ET
DEADLINE ALERT for BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 31, 2023 03:35 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 30, 2023 10:20 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of BioXcel Therapeutics, Inc. - BTAI
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of BioXcel Therapeutics, Inc. (NasdaqCM: BTAI), if they purchased the Company’s securities between December 15, 2021 and June 28, 2023, inclusive (the “Class...
Aug 30, 2023 01:07 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioXcel Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2023 – (NASDAQ: BTAI)
The Gross Law Firm issues the following notice to shareholders of BioXcel Therapeutics, Inc. Shareholders who purchased shares of BTAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment....
Aug 30, 2023 12:04 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioXcel Therapeutics, Inc....
Aug 30, 2023 05:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 29, 2023 09:25 pm ET
BIOXCEL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 5, 2023 to file lead plaintiff applications in a securities class action lawsuit against BioXcel Therapeutics, Inc. (NasdaqCM: BTAI), if they...
Aug 29, 2023 05:00 am ET
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 29, 2023 01:45 am ET
BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXc
Bernstein Liebhard LLP: Do you, or did you, own shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI)?Did you purchase your shares between December 15, 2021 and June 28, 2023, inclusive?Did you lose money in your investment in BioXcel Therapeutics,...
Aug 28, 2023 01:34 pm ET
BTAI 8-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages BioXcel Therapeutics (BTAI) Investors with Substantial Losses to Contact Firm’s Attorneys Before Sept. 5th Deadline in Se
Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period: Dec. 15, 2021 – June 28, 2023Lead Plaintiff Deadline: Sept. 5, 2023Visit:...
Aug 28, 2023 01:10 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. (BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were...
Aug 28, 2023 11:13 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 28, 2023 10:00 am ET
Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) and certain of...
Aug 28, 2023 05:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 27, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioXcel, Seagate, and Baxter and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI), Seagate Technology Holdings Plc...
Aug 27, 2023 05:56 pm ET
BTAI Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of September 5, 2023 Deadline in Securities Fraud Class Action Lawsuit against BioXcel Therapeutics, Inc. (BTAI)
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut against BioXcel Therapeutics, Inc....
Aug 26, 2023 02:03 pm ET
ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action – BTAI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”), of the important September...
Aug 26, 2023 12:38 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI
Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Aug 25, 2023 12:27 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioXcel Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2023 – (NASDAQ: BTAI)
The Gross Law Firm issues the following notice to shareholders of BioXcel Therapeutics, Inc.. Shareholders who purchased shares of BTAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Aug 25, 2023 06:00 am ET
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 24, 2023 12:50 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. (BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were...
Aug 24, 2023 10:05 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 24, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 23, 2023 03:17 pm ET
BTAI Investors Should Contact Robbins LLP About Participating in the Class Action Against BioXcel Therapeutics
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioXcel Therapeutics, Inc. (NASDAQ: BTAI) securities between December 15, 2021 and June 28, 2023....
Aug 23, 2023 11:03 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioXcel Therapeutics, Inc....
Aug 23, 2023 06:00 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 23, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 22, 2023 10:44 pm ET
BIOXCEL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bi
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 5, 2023 to file lead plaintiff applications in a securities class action lawsuit against...
Aug 22, 2023 12:21 pm ET
BTAI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc. Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws. Class Period: December 15, 2021 to June...
Aug 22, 2023 11:11 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 22, 2023 07:00 am ET
BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel
Do you, or did you, own shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI)? Did you purchase your shares between December 15, 2021 and June 28, 2023, inclusive? Did you lose money in your investment in BioXcel Therapeutics, Inc.? Do...
Aug 22, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 21, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ImmunityBio, BioXcel, and Seagate and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of ImmunityBio, Inc. (NASDAQ: IBRX), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), and...
Aug 21, 2023 03:56 pm ET
BioXcel Therapeutics, Inc: Please contact the Portnoy Law Firm to recover your losses; September 5, 2023 deadline.
The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) investors that a lawsuit filed on behalf of investors that purchased BioXcel securities between December 15, 2021 and June 28, 2023, both dates...
Aug 21, 2023 02:07 pm ET
BTAI CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages BioXcel Therapeutics (BTAI) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending
Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period: Dec. 15, 2021 – June 28, 2023Lead Plaintiff Deadline: Sept. 5, 2023Visit:...
Aug 21, 2023 02:06 pm ET
BTAI CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages BioXcel Therapeutics (BTAI) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending
Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period: Dec. 15, 2021 – June 28, 2023Lead Plaintiff Deadline: Sept. 5, 2023Visit:...
Aug 21, 2023 01:13 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioXcel Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2023 – (NASDAQ: BTAI)
The Gross Law Firm issues the following notice to shareholders of BioXcel Therapeutics, Inc.. Shareholders who purchased shares of BTAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Aug 21, 2023 10:00 am ET
Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) and certain of...
Aug 21, 2023 09:45 am ET
BTAI LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving BioXcel Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / August 21, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased BioXcel Therapeutics, Inc. ("BioXcel") (NASDAQ:BTAI) between December 15, 2021 and June 28, 2023.
Aug 21, 2023 06:00 am ET
INVESTOR DEADLINE ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ: BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 20, 2023 01:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI
Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Aug 20, 2023 11:22 am ET
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”), of the important September...
Aug 19, 2023 10:33 am ET
Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut against BioXcel Therapeutics, Inc....
Aug 19, 2023 07:00 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ: BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 18, 2023 12:24 pm ET
BTAI LAWSUIT ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were...
Aug 18, 2023 09:45 am ET
BTAI LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving BioXcel Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / August 18, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased BioXcel Therapeutics, Inc. ("BioXcel") (NASDAQ:BTAI) between December 15, 2021 and June 28, 2023.
Aug 18, 2023 05:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 17, 2023 12:47 pm ET
DEADLINE ALERT for BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 16, 2023 10:36 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of BioXcel Therapeutics, Inc. - BTAI
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of BioXcel Therapeutics, Inc. (NasdaqCM: BTAI), if they purchased the Company’s securities between December 15, 2021 and June 28, 2023, inclusive (the “Class...
Aug 16, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ImmunityBio, BioXcel, and Seagate and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of ImmunityBio, Inc. (NASDAQ: IBRX), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), and...
Aug 16, 2023 06:45 pm ET
BTAI LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving BioXcel Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / August 16, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased BioXcel Therapeutics, Inc. ("BioXcel") (NASDAQ:BTAI) between December 15, 2021 and June 28, 2023.
Aug 16, 2023 06:45 pm ET
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”), of the important...
Aug 16, 2023 11:58 am ET
BTAI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc. Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws. Class Period: December 15, 2021 to June...
Aug 15, 2023 10:06 pm ET
BIOXCEL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 5, 2023 to file lead plaintiff applications in a securities class action lawsuit against BioXcel Therapeutics, Inc. (NasdaqCM: BTAI), if they...
Aug 15, 2023 12:01 pm ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind BioXcel Investors of a Lead Plaintiff Deadline of September 5, 2023
Attention BioXcel Therapeutics, Inc. ("BioXcel") (NASDAQ: BTAI) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between December 15, 2021 and June 28, 2023. If...
Aug 15, 2023 11:15 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 14, 2023 07:20 pm ET
Lost Money in BioXcel Therapeutics, Inc? Gibbs Law Group Investigates Potential Securities Law Violations
Gibbs Law Group reminds investors that a class action lawsuit has been filed against BioXcel Therapeutics, Inc. (NASDAQ: BTAI), on behalf of investors who purchased or acquired shares between December 15, 2021, and June 28, 2023, inclusive. Shares of BioXcel dropped 65% o
Aug 14, 2023 05:55 pm ET
BioXcel Therapeutics, Inc Investors: Please contact the Portnoy Law Firm to recover your losses; September 5, 2023 deadline
The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI). investors that a lawsuit filed on behalf of investors that purchased BioXcel securities between December 15, 2021 and June 28, 2023, both dates...
Aug 14, 2023 12:58 pm ET
BTAI LAWSUIT ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were...
Aug 14, 2023 11:53 am ET
RAIN, PTRA, BTAI, Class Action Update: Johnson Fistel Alerts Shareholders of Ongoing Legal Proceedings
Johnson Fistel, LLP, a law firm specializing in shareholder rights, has announced the initiation of class action lawsuits on behalf of investors of the following companies. Investors are encouraged to review the deadlines listed and submit their...
Aug 14, 2023 11:07 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioXcel Therapeutics, Inc....
Aug 14, 2023 10:00 am ET
Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) and certain of...
Aug 14, 2023 07:00 am ET
BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the second...
Aug 14, 2023 01:45 am ET
BTAI DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.
Do you, or did you, own shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI)?Did you purchase your shares between December 15, 2021 and June 28, 2023, inclusive?Did you lose money in your investment in BioXcel Therapeutics, Inc.?Do you want to...
Aug 12, 2023 01:36 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI
Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Aug 11, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GDS, Arrow, ImmunityBio, and BioXcel and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of GDS Holdings Limited (NASDAQ: GDS), Arrow Financial Corporation (NASDAQ: AROW),...
Aug 11, 2023 01:27 pm ET
Kessler Topaz Meltzer & Check, LLP Reminds BTAI Investors of September 5, 2023 Deadline in Securities Fraud Class Action against of BioXcel Therapeutics, Inc. and Urges Investors with Substantial Loss
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut against BioXcel Therapeutics, Inc....
Aug 11, 2023 12:38 pm ET
BTAI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc. Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws. Class Period: December 15, 2021 to June...
Aug 10, 2023 12:01 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioXcel Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2023 – (NASDAQ: BTAI)
The Gross Law Firm issues the following notice to shareholders of BioXcel Therapeutics, Inc.. Shareholders who purchased shares of BTAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Aug 10, 2023 09:00 am ET
DEADLINE ALERT for BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 09, 2023 01:24 pm ET
BTAI SHAREHOLDER ALERT: Jakubowitz Law Reminds BioXcel Shareholders of a Lead Plaintiff Deadline of September 5, 2023
Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI). To receive updates on the lawsuit, fill out the...
Aug 09, 2023 11:17 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 08, 2023 11:20 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 9, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 08, 2023 11:03 pm ET
BIOXCEL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bi
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 5, 2023 to file lead plaintiff applications in a securities class action lawsuit against...
Aug 08, 2023 01:14 pm ET
BTAI LAWSUIT ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were...
Aug 08, 2023 06:00 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 08, 2023 01:45 am ET
BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel
Bernstein Liebhard LLP: Do you, or did you, own shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI)?Did you purchase your shares between December 15, 2021 and June 28, 2023, inclusive?Did you lose money in your investment in BioXcel Therapeutics,...
Aug 07, 2023 01:48 pm ET
BTAI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc. Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws. Class Period: December 15, 2021 to June...
Aug 07, 2023 10:00 am ET
Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) and certain of...
Aug 07, 2023 02:30 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 06, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioXcel, Seagate, Baxter, and Danaher and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI), Seagate Technology Holdings Plc...
Aug 06, 2023 10:28 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ: BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 05, 2023 07:50 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ: BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 04, 2023 12:43 pm ET
BTAI LAWSUIT ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were...
Aug 04, 2023 11:07 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioXcel Therapeutics, Inc....
Aug 04, 2023 10:08 am ET
RAIN, PTRA, BTAI, Class Action Update: Johnson Fistel Alerts Shareholders of Ongoing Legal Proceedings
Johnson Fistel, LLP, a law firm specializing in shareholder rights, has announced the initiation of class action lawsuits on behalf of investors of the following companies. Investors are encouraged to review the deadlines listed and submit their...
Aug 04, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 03, 2023 05:13 pm ET
DEADLINE ALERT for BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 03, 2023 03:45 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioXcel Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2023 – (NASDAQ: BTAI)
The Gross Law Firm issues the following notice to shareholders of BioXcel Therapeutics, Inc. Shareholders who purchased shares of BTAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment....
Aug 03, 2023 09:55 am ET
BioXcel Therapeutics, Inc. Class Action Notice: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. (BTAI) Shareholders of Securities Fraud Class Action Lawsuit and Encourages Invest
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut against BioXcel Therapeutics, Inc....
Aug 03, 2023 09:00 am ET
BIOXCEL THERAPEUTICS, INC. INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies BTAI Investors of a Class Action Lawsuit and Upcoming Deadline
Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of persons and entities that purchased or acquired securities of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) securities between...
Aug 03, 2023 06:00 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 02, 2023 10:53 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of BioXcel Therapeutics, Inc. - BTAI
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of BioXcel Therapeutics, Inc. (NasdaqCM: BTAI), if they purchased the Company’s securities between December 15, 2021 and June 28, 2023, inclusive (the “Class...
Aug 02, 2023 04:05 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI
Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Aug 02, 2023 02:55 pm ET
BTAI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc. Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws. Class Period: December 15, 2021 to June...
Aug 02, 2023 11:15 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 02, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioXcel Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2023 - (NASDAQ: BTAI)
NEW YORK, Aug. 2, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioXcel Therapeutics, Inc..
Aug 01, 2023 10:43 pm ET
BIOXCEL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 5, 2023 to file lead plaintiff applications in a securities class action lawsuit against BioXcel Therapeutics, Inc. (NasdaqCM: BTAI), if they...
Aug 01, 2023 04:36 pm ET
Lost Money in BioXcel Therapeutics, Inc? Gibbs Law Group Investigates Potential Securities Law Violations
Gibbs Law Group reminds investors that a class action lawsuit has been filed against BioXcel Therapeutics, Inc. (NASDAQ: BTAI), on behalf of investors who purchased or acquired shares between December 15, 2021, and June 28, 2023, inclusive. Shares of BioXcel dropped 65% o
Aug 01, 2023 12:48 pm ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind BioXcel Investors of a Lead Plaintiff Deadline of September 5, 2023
Attention BioXcel Therapeutics, Inc. ("BioXcel") (NASDAQ: BTAI) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between December 15, 2021 and June 28, 2023....
Aug 01, 2023 09:35 am ET
BTAI Investors Have Opportunity to Lead BioXcel Therapeutics, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., Aug. 1, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI).
Aug 01, 2023 06:00 am ET
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 01, 2023 05:45 am ET
BTAI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc. Shareholders
NEW YORK, Aug. 1, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws.
Aug 01, 2023 01:45 am ET
BTAI DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.
Bernstein Liebhard LLP: Do you, or did you, own shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI)?Did you purchase your shares between December 15, 2021 and June 28, 2023, inclusive? Did you lose money in your investment in BioXcel...
Jul 31, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Seagate, Baxter, and BioXcel and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Seagate Technology Holdings Plc (NASDAQ: STX), Baxter International, Inc. (NYSE:...
Jul 31, 2023 06:00 pm ET
ROSEN, LEADING INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”), of the important...
Jul 31, 2023 12:52 pm ET
BTAI LAWSUIT ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were...
Jul 31, 2023 11:39 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages BioXcel Therapeutics (BTAI) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed
Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period: Dec. 15, 2021 – June 28, 2023Lead Plaintiff Deadline: September 5, 2023Visit:...
Jul 31, 2023 10:00 am ET
Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) and certain of...
Jul 31, 2023 07:00 am ET
BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its second quarter...
Jul 31, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 31, 2023 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind BioXcel Investors of a Lead Plaintiff Deadline of September 5, 2023
NEW YORK, July 31, 2023 /PRNewswire/ -- Attention BioXcel Therapeutics, Inc. ("BioXcel") (NASDAQ: BTAI) shareholders:
Jul 30, 2023 04:04 pm ET
Kessler Topaz Meltzer & Check, LLP Notification: Deadline Reminder for BioXcel Therapeutics, Inc. (BTAI) Investors in Securities Class Action Lawsuit
RADNOR, Pa., July 30, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut against BioXcel Therapeutics, Inc. ("BioXcel") (NASDAQ: BTAI). The action charges BioXcel with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of BioXcel's materially misleading statements and omissions to the public, Bio
Jul 29, 2023 07:00 am ET
BIOXCEL SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options
NEW YORK, July 29, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) and reminds investors of the September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Jul 29, 2023 07:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ: BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 28, 2023 10:50 pm ET
BIOXCEL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI
NEW ORLEANS, July 28, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 5, 2023 to file lead plaintiff applications in a securities class action lawsuit against BioXcel Therapeutics, Inc. (NasdaqCM: BTAI), if they purchased the Company's securities between December 15, 2021 and June 28, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Connecticut.
Jul 28, 2023 12:43 pm ET
BTAI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc. Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws. Class Period: December 15, 2021 to June...
Jul 28, 2023 11:07 am ET
DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 28, 2023 11:00 am ET
BTAI Investors Have Opportunity to Lead BioXcel Therapeutics, Inc. Securities Fraud Lawsuit
LOS ANGELES, July 28, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI).
Jul 28, 2023 06:00 am ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 28, 2023 05:45 am ET
BTAI SHAREHOLDER ALERT: Jakubowitz Law Reminds BioXcel Shareholders of a Lead Plaintiff Deadline of September 5, 2023
NEW YORK, July 28, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI).
Jul 27, 2023 09:00 pm ET
BIOXCEL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioXcel Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) in the United States District Court for the District of Connecticut on behalf of all persons and entities who purchased or otherwise acquired BioXcel securities between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”). Investors have until September 5, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jul 27, 2023 03:17 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI
Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jul 27, 2023 12:58 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioXcel Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2023 – (NASDAQ: BTAI)
The Gross Law Firm issues the following notice to shareholders of BioXcel Therapeutics, Inc. Shareholders who purchased shares of BTAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment....
Jul 27, 2023 10:30 am ET
DEADLINE ALERT for BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 27, 2023 08:43 am ET
BTAI DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in BioXcel Therapeutics, Inc. Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut against BioXcel Therapeutics, Inc....
Jul 27, 2023 05:45 am ET
BTAI LAWSUIT ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, July 27, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit.
Jul 27, 2023 01:50 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of BioXcel Therapeutics, Inc. - BTAI
CEDARHURST, N.Y., July 27, 2023 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of BioXcel Therapeutics, Inc. (NasdaqCM: BTAI), if they purchased the Company's securities between December 15, 2021 and June 28, 2023, inclusive (the "Class Period").  Shareholders have until September 5, 2023 to file lead plaintiff applications in the securities class action lawsuit.
Jul 26, 2023 12:42 pm ET
BTAI SHAREHOLDER ALERT: Jakubowitz Law Reminds BioXcel Shareholders of a Lead Plaintiff Deadline of September 5, 2023
Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI). To receive updates on the lawsuit, fill out the...
Jul 26, 2023 11:07 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioXcel Therapeutics, Inc....
Jul 26, 2023 06:00 am ET
INVESTOR DEADLINE ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 26, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioXcel Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2023 - (NASDAQ: BTAI)
NEW YORK, July 26, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioXcel Therapeutics, Inc..
Jul 25, 2023 11:36 pm ET
BIOXCEL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bi
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 5, 2023 to file lead plaintiff applications in a securities class action lawsuit against...
Jul 25, 2023 03:32 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI
NEW YORK, July 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 25, 2023 03:11 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds BioXcel Therapeutics (BTAI) Investors of Securities Fraud Class Action, Encourages Investors with Substantial Losses to Contact Firm’s Attorneys
Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period: Dec. 15, 2021 – June 28, 2023Lead Plaintiff Deadline: September 5, 2023Visit:...
Jul 25, 2023 02:11 pm ET
BTAI LAWSUIT ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were...
Jul 25, 2023 07:00 am ET
BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXc
Bernstein Liebhard LLP: Do you, or did you, own shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI)?Did you purchase your shares between December 15, 2021 and June 28, 2023, inclusive? Did you lose money in your investment in BioXcel...
Jul 25, 2023 05:45 am ET
BTAI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc. Shareholders
NEW YORK, July 25, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws.
Jul 24, 2023 05:53 pm ET
BioXcel Therapeutics, Inc: Please contact the Portnoy Law Firm to recover your losses; September 5, 2023 deadline
The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI). investors that a lawsuit filed on behalf of investors that purchased BioXcel securities between December 15, 2021 and June 28, 2023, both dates...
Jul 24, 2023 02:05 pm ET
BTAI Investors Have Opportunity to Lead BioXcel Therapeutics, Inc. Securities Fraud Lawsuit
LOS ANGELES, July 24, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI).
Jul 24, 2023 12:45 pm ET
BTAI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc. Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws. Class Period: December 15, 2021 to June...
Jul 24, 2023 10:00 am ET
Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) and certain of...
Jul 24, 2023 06:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 22, 2023 04:30 pm ET
BTAI INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of persons and entities that purchased or acquired securities of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) securities between...
Jul 22, 2023 04:12 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”), of the important September...
Jul 22, 2023 07:00 am ET
BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options
NEW YORK, July 22, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) and reminds investors of the September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Jul 21, 2023 10:50 pm ET
BIOXCEL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bi
NEW ORLEANS, July 21, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 5, 2023 to file lead plaintiff applications in a securities class action lawsuit against BioXcel Therapeutics, Inc. (NasdaqCM: BTAI), if they purchased the Company's securities between December 15, 2021 and June 28, 2023, inclusive (the "Class Period").  This action is pending in the United States District Court for the District of Connecticut.
Jul 21, 2023 03:38 pm ET
BTAI Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against BioXcel Therapeutics, Inc. (BTAI) and Encourages Invest
RADNOR, Pa., July 21, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut against BioXcel Therapeutics, Inc. ("BioXcel") (NASDAQ: BTAI). The action charges BioXcel with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.  As a result of BioXcel's materially misleading statements and omissions to the public, Bi
Jul 21, 2023 12:53 pm ET
BTAI LAWSUIT ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were...
Jul 21, 2023 12:50 pm ET
DEADLINE ALERT for BTAI, MNK, STX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 21, 2023 05:45 am ET
BTAI SHAREHOLDER ALERT: Jakubowitz Law Reminds BioXcel Shareholders of a Lead Plaintiff Deadline of September 5, 2023
NEW YORK, July 21, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI).

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.